NVS Stock Recent News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases.

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, development and commercial milestones Matchpoint will lead all research activities through development candidate selection WATERTOWN, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Matchpoint Therapeutics, a biotechnology company pioneering the discovery of precision covalent medicines, today announced that it has entered into an exclusive option and license agreement with Novartis for the development and commercialization of oral covalent inhibitors directed at a transcription factor linked to a number of inflammatory diseases.

J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.

Novartis AG (NYSE:NVS ) Q2 2025 Earnings Conference Call July 17, 2025 8:00 AM ET Company Participants Harry Kirsch - Chief Financial Officer Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Conference Call Participants Emmanuel Douglas Papadakis - Deutsche Bank AG, Research Division Florent Cespedes - Societe Generale Cross Asset Research Harry Thomas d'Alton Sephton - Crédit Suisse AG, Research Division James Patrick Quigley - Goldman Sachs Group, Inc., Research Division Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Michael Leuchten - UBS Investment Bank, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Peter Verdult - BNP Paribas Exane, Research Division Rajesh Kumar - HSBC Global Investment Research Richard Vosser - JPMorgan Chase & Co, Research Division Sachin Jain - BofA Securities, Research Division Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division Shirley

President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country.

With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.

Here is what you may have missed on Market Catalysts for Thursday, July 17. Uber and Lucid are partnering on a new robotaxi service.

Novartis CEO Vas Narasimhan said Thursday that the company is in open discussions with the Trump administration over pharmaceutical tariffs, aiming to strike a balance between lowering patient costs and preserving U.S. leadership in biomedical innovation.